This discussion examines the key considerations oncologists weigh when choosing between chemotherapy alone or chemotherapy ...

This discussion provides a clear overview of current treatment standards and ongoing challenges in the management of advanced ...

Treatment responses to Xalkori were not affected by PD-L1 expression in patients with advanced non-small cell lung cancer and ROS1 rearrangements. Patients with advanced non-small cell lung cancer ...

The US Patent and Trademark Office (USPTO) has granted a patent to Genprex for the use of its Reqorsa gene therapy in ...

Longer follow-up in the IMpower010 trial further cemented the value of atezolizumab (Tecentriq) in treating stage II-IIIa non-small cell lung cancer (NSCLC) in patients with tumors expressing PD-L1.

Immune checkpoint therapy, particularly anti-PD-1/PD-L1 immunotherapy, have achieved significant results in the treatment of various tumors. However, most cancer patients show a low response rate to ...

Recently, the research group of Prof. HUANG Qing at Hefei Institutes of Physical Science, Chinese Academy of Sciences developed DNA-aptamer based surface enhanced Raman spectroscopy (SERS) probes for ...

Absent tools such as rebate reform, transparent pricing or accelerated biosimilar substitution, true price competition will ...

With Bristol Myers Squibb (BMS) now rolling out the SC version of rival nivolumab (Opdivo Qvantig), the shift from 30-minute intravenous (IV) infusion to 5-minute SC injection could be one of the most ...

Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing ...